monoclonal antibodies against igg1  (SouthernBiotech)

Journal: bioRxiv

Article Title: In vivo, online label-free monitoring of heterogenous oxygen utilization during phototherapy with real-time ultrasound-guided photoacoustic imaging

doi: 10.1101/2024.11.27.625759

Figure Lengend Snippet: a) H&E and b) US B-scan images show structural similarities in the tumor while c) immunofluorescence images with pimonidazole stain (yellow regions) correlates to low-StO 2 regions in d) PA images for 3 distinct tumors. Red arrows highlight areas of correlation between high StO 2 and low pimonidazole signal while blue arrows highlight areas with low StO 2 and high pimonidazole signal. Scale bars represent 2 mm.

Article Snippet: Primary antibody for targeting vasculature (Mouse CD31/PECAM-1 Polyclonal Goat IgG, Cat: AF3628; R&D Systems, 1:5 dilution) and antibody against pimonidazole adducts (conjugated IgG1 rat monoclonal antibody clone 11.23.22.r, Cat: Red 549 Mab; Hypoxyprobe, 1:25 dilution) were added to the sections and incubated overnight at 4 °C.

Techniques: Immunofluorescence, Staining

Journal: bioRxiv

Article Title: In vivo, online label-free monitoring of heterogenous oxygen utilization during phototherapy with real-time ultrasound-guided photoacoustic imaging

doi: 10.1101/2024.11.27.625759

Figure Lengend Snippet: a) Schematic of the non-uniform light dose arrangement. b) Normalized StO 2 over the PDT timeline in the ROIs for left half, right half, and whole tumor segments. c) US B-scan image of the tumor with left and right half ROIs and d) matching H&E histology image. e-j) Associated PAI StO 2 images for annotated timepoints in b). k) CD31 and l) TL stains of the cross-section matching the PA image. m) Difference of frames g (end of active-PDT) and j (end of scan) showing areas of re-oxygenation. White arrows highlight regions of correlation between functional vessels in the TL stain and re-oxygenation in m. n) Pimonidazole matches with low-StO 2 regions in o) the corresponding frame from the post-PDT 3D PA image. Red arrows highlight areas of correlation between high StO 2 and low pimonidazole while blue arrows highlight areas with low StO 2 and high pimonidazole. Scale bars = 2 mm. Video. S2 shows the movie of all PA StO 2 images captured pre, during, and post-PDT.

Article Snippet: Primary antibody for targeting vasculature (Mouse CD31/PECAM-1 Polyclonal Goat IgG, Cat: AF3628; R&D Systems, 1:5 dilution) and antibody against pimonidazole adducts (conjugated IgG1 rat monoclonal antibody clone 11.23.22.r, Cat: Red 549 Mab; Hypoxyprobe, 1:25 dilution) were added to the sections and incubated overnight at 4 °C.

Techniques: Functional Assay, Staining

Journal: medRxiv

Article Title: Linoleoyl-lysophosphatidylcholine suppresses immune-related adverse events due to immune checkpoint blockade

doi: 10.1101/2024.08.07.24310974

Figure Lengend Snippet: ( a ) Heat map of LPC associations with immune cellularity by multi-color flow cytometry in 500FG (n = 488). Color = effect size with p < 0.05. ( b ) Circulating LPC 18:2 associations by linear regression with serum immunoglobulin titers in 500FG (IgG [7.00-16.00 gram/Liter]; IgA [0.70-4.00 gram/Liter]; IgM [0.40-2.30 gram/Liter]; IgG1 [4.90-11.40 gram/Liter]; IgG2 [1.50-6.40 gram/Liter]; IgG3 [0.20-1.10 gram/Liter]; IgG4 [0.08-1.40 gram/Liter].

Article Snippet: LPC production was determined via an adaptation of the method delineated by Mouchlis et al . Where indicated, rat anti-mouse IgG1 monoclonal antibodies against TNF alpha (MP6-XT22), IL-6 (MP5-20F3), or a control antigen (eBRG1) (eBioscience) were administered intraperitoneally six hours prior to isolation for acute cytokine inhibition.

Techniques: Flow Cytometry

Journal: medRxiv

Article Title: Linoleoyl-lysophosphatidylcholine suppresses immune-related adverse events due to immune checkpoint blockade

doi: 10.1101/2024.08.07.24310974

Figure Lengend Snippet: ( a ) Diagram of experimental design for CTLA-4 h/h model of ICB-irAE and DSS colitis. ( b ) LPC 18:2 concentration in terminal blood of CTLA-4 h/h C57BL/6 mice treated with 100 ug anti-human IgG1 isotype control (hIgFc), 100 ug ipilimumab (Ipi), or 100 ug ipilimumab + 100 ug anti-mouse PD-1 monoclonal antibody (Ipi + anti-PD-1). n = 4 per group. Error = SD. Bar = mean. Right: correlation plot of LPC 18:2 concentration to pathology score. Linear regression in dark red, 95% confidence interval in light red. ( c ) LPC 18:2 rate of production from blood plasma on Day 28 after ipilimumab + anti-PD-1 therapy CTLA-4 h/h mice. n = 4 per group. Error = SD. Bar = mean. ( d ) LPC 18:2 concentration in terminal blood of 2.5% DSS-treated C57BL/6. n = 5 per group. Error = SD. Bar = mean. ( e ) De novo LPC 18:2 production in terminal blood of 2.5% DSS mice treated with 100ug control IgG, 100ug anti-TNF, or 100ug anti-IL-6 for 6 hours. n = 3-5 per group, Error = SD. Bar = mean. ( f ) Quartiles of IL-6 cytokine (pg/mL) and LPC 18:2 concentration in 500FG. Bars = mean. Student’s T-test ( , ), one-way ANOVA with Dunnett’s multiple comparisons test ( , , ).

Article Snippet: LPC production was determined via an adaptation of the method delineated by Mouchlis et al . Where indicated, rat anti-mouse IgG1 monoclonal antibodies against TNF alpha (MP6-XT22), IL-6 (MP5-20F3), or a control antigen (eBRG1) (eBioscience) were administered intraperitoneally six hours prior to isolation for acute cytokine inhibition.

Techniques: Concentration Assay, Control, Clinical Proteomics

Journal: medRxiv

Article Title: Linoleoyl-lysophosphatidylcholine suppresses immune-related adverse events due to immune checkpoint blockade

doi: 10.1101/2024.08.07.24310974

Figure Lengend Snippet: ( a ) Diagram of experimental design for LPC 18:2 intraperitoneal administration in ICB-treated CTLA-4 h/h mice and DSS colitis. ( b ) Histology score and representative H&E staining in distal colon of CTLA-4 h/h mice following intraperitoneal administration of 100 ug anti-human IgG1 isotype control (hIgFc) or 100 ug ipilimumab + 100 ug anti-mouse PD-1 monoclonal antibody (ICB), dosed as above, n = 7-8 per group. Error = SD, Bar = mean, ruler = 100µm ( c ) Histology score and representative H&E staining in distal colon of DSS-treated mice. LPC 18:2 was administered at 25 mg/kg on Days 0, 2, 4, and 6 of DSS treatment. n = 5 per group. Bar = mean, ruler = 200µm. ( d ) Mean LPC 18:2 concentration and neutrophil (CD45 + , CD11b + , Ly6G + ) numbers in CTLA-4 h/h mouse blood. n = 5 per group. Error = SEM. ( e ) Multi-color flow cytometry of blood neutrophils in 2.5% DSS-colitis mice following treatment with 25 mg/kg of LPC 18:2. One-way ANOVA with Dunnett’s multiple comparisons test ; two-way ANOVA with Sidak multiple comparisons test ( , 4e ).

Article Snippet: LPC production was determined via an adaptation of the method delineated by Mouchlis et al . Where indicated, rat anti-mouse IgG1 monoclonal antibodies against TNF alpha (MP6-XT22), IL-6 (MP5-20F3), or a control antigen (eBRG1) (eBioscience) were administered intraperitoneally six hours prior to isolation for acute cytokine inhibition.

Techniques: Staining, Control, Concentration Assay, Flow Cytometry

Journal: medRxiv

Article Title: Linoleoyl-lysophosphatidylcholine suppresses immune-related adverse events due to immune checkpoint blockade

doi: 10.1101/2024.08.07.24310974

Figure Lengend Snippet: ( a-b ) Percent weight loss ( a ) and colon length relative to starting body weight ( b ) in 5% DSS treated mice following LPC 18:2 supplementation. N = 5 per group. Bar = mean. ( c ) Toxicity score in cecum and distal colon of 5% DSS treated mice following LPC (16:0) supplementation. n = 5 per group. Bar = mean. ( d ) Colon length relative to starting body weight in 5% DSS treated mice following supplementation with saturated and unsaturated C18-LPCs. n = 5 per group. Bar = mean. ( e ) Percent baseline weight in C57BL/6 mice receiving 2.5% DSS treated with 100ug control IgG, 100ug anti-TNF, or 100ug anti-IL-6 for 6 hours. n = 3-5 per group, Error = SD. Bar = mean. One-way ANOVA with Dunnett’s multiple comparisons test ; two-way ANOVA with Sidak’s multiple comparisons test .

Article Snippet: LPC production was determined via an adaptation of the method delineated by Mouchlis et al . Where indicated, rat anti-mouse IgG1 monoclonal antibodies against TNF alpha (MP6-XT22), IL-6 (MP5-20F3), or a control antigen (eBRG1) (eBioscience) were administered intraperitoneally six hours prior to isolation for acute cytokine inhibition.

Techniques: Control